# ZZ Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zz-biotech

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.zzbiotech.com
- Total disclosed funding: $1M
- Latest round: Seed (May 13, 2014)
- Investors on record: 1

## About

ZZ Biotech LLC is a biotechnology company focused on developing advanced therapeutic solutions, specifically a genetically engineered variant of human activated protein C to enhance wound healing in patients.Founded in 2006 and headquartered in San Diego, US, ZZ Biotech LLC specializes in the development of therapeutic products. The company has engaged in strategic business pivots, including entering licensing agreements with Dermatherix, Pty Ltd, to advance its clinical applications. The current CEOs are Joseph Romano and Kent Pryor. The company has completed 2 deals, with the most recent deal occurring on January 1, 2015, raising USD 6.9 mn in funding, which represents the total amount raised to date.ZZ Biotech specializes in the development of 3K3A-APC, a genetically engineered variant of human activated protein C (APC), designed for therapeutic applications in humans. This innovative product targets various wound healing scenarios and aims to enhance recovery in dermatological conditions. Through its partnership with Dermatherix, ZZ Biotech is working to advance the clinical applications of 3K3A-APC. The primary customers include healthcare providers and patients requiring advanced wound therapies, especially in regions with a high incidence of chronic wounds, such as North America, Europe, and parts of Asia.ZZ Biotech's revenue model is built on strategic licensing agreements, particularly with Dermatherix, to support the distribution and commercialization of 3K3A-APC. The company engages in B2B transactions, collaborating with biotech firms and healthcare providers to integrate its therapeutic solutions into existing treatment protocols. Revenue is generated through licensing fees and potential royalties based on the sales of 3K3A-APC across therapeutic markets, with pricing structures tailored to meet the unique needs of healthcare partners and end-users.ZZ Biotech plans to leverage the USD 6.9 mn raised from its latest funding round in January 2015 to support the continued development of 3K3A-APC and its clinical applications. The company aims to expand its market presence in North America and Europe, targeting the introduction of new products designed to address specific wound healing challenges by 2025. Through its strategic partnerships, ZZ Biotech intends to enhance its distribution capabilities and explore new geographic markets in Asia, which are experiencing rising demands for advanced wound therapies.

## Funding rounds

- Seed, May 13, 2014, $1M — Broadview Ventures

## Investors

- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Seed